


A

Hybrid vaccination

Mass vaccination



Target reduction (%)

0 5 10 15 20 25 30 35 40 45 50 55 60


B

Hybrid vaccination

Mass vaccination

Infection
prevalenceClinical
incidenceSevere
disease

Median relative reduction (%)

Infection
prevalenceClinical
incidenceSevere
disease**Tradeoffs**

Coverage 90% Efficacy 90% Coverage 90% Efficacy 50% Coverage 50% Efficacy 90% Coverage 50% Efficacy 50%